We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes (REPLACE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02082184
First Posted: March 10, 2014
Last Update Posted: May 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Abbott Diabetes Care
  Purpose
To evaluate the impact of the Abbott Sensor Based Glucose Monitoring System on glycaemic control (HbA1c) compared to Self Monitoring Blood Glucose (SMBG) testing using a randomised controlled study design in adults with Type 2 diabetes using insulin.

Condition Intervention
Type 2 Diabetes Mellitus Device: Sensor Based Glucose Monitoring System Device: Standard Blood Glucose Monitoring

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Randomised Controlled Study to Evaluate the Impact of Novel Glucose Sensing Technology on HbA1c in Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Abbott Diabetes Care:

Primary Outcome Measures:
  • HbA1c at 6 Months [ Time Frame: Baseline and Day 194 ]
    Difference in HbA1c between intervention and control group at day 194 adjusting for baseline HbA1c at day 1 using ANCOVA.


Secondary Outcome Measures:
  • Time in Range [ Time Frame: Baseline and Days 194 to 208 ]
    Difference in time in range 70-180 mg/dL between intervention and control group assessed in days 194 to 208 adjusting for baseline (days 1 to 15 time in range) using ANCOVA.

  • Time Spent <70 mg/dL and <55 mg/dL [ Time Frame: Baseline and Days 194 to 208 ]
    Difference in time <70 mg/dL and <55 mg/dL (hours per day) between intervention and control group assessed in days 194 to 208 adjusting for baseline (days 1 to 15) using ANCOVA.

  • Frequency of Episodes <70 mg/dL and <55 mg/dL [ Time Frame: Baseline and Days 194 to 208 ]
    Difference in frequency of episodes <70 mg/dL and <55 mg/dL (number per day) between intervention and control group assessed in days 194 to 208 adjusting for baseline (days 1 to 15) using ANCOVA.

  • Time Spent >180 mg/dL and >240 mg/dL [ Time Frame: Baseline and Days 194 to 208 ]
    Difference in time >180 mg/dL and >240mg/dL (hours per day) between intervention and control group assessed in days 194 to 208 adjusting for baseline (days 1 to 15) using ANCOVA.

  • Number of Glucose Measurements Performed [ Time Frame: Days 15 to 208 ]
    Number of blood glucose fingerstick tests per day by intervention and control group during days 15 to 208. The number of sensor scans performed by the intervention group during days 15 to 208.

  • System Utilisation [ Time Frame: Days 15 to 208 ]
    Sensor utilisation assessed by percentage of sensor glucose data collected by the intervention group.

  • Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 194. [ Time Frame: Baseline and Day 194 ]

    The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale (which ranges from -3 (much less satisfied) to +3 (much more satisfied). The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied).

    There is one question to assess the change in perceived frequency of Hypoglycaemia and one question to assess change in perceived frequency of Hyperglycaemia. Each question is rated on a 7-point Likert scale (-3 to +3), -3 (much less of the time now) to +3 (much more of the time now).

    The ANCOVA adjusts for baseline DTSQs (status version).



Enrollment: 302
Study Start Date: March 2014
Study Completion Date: December 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sensor Based Glucose Monitoring System
Standard system use for 6 months. Followed by open access to the device for 6 months.
Device: Sensor Based Glucose Monitoring System

Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.

All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.

Active Comparator: Standard Blood Glucose Monitoring
Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
Device: Standard Blood Glucose Monitoring

Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.

All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.


  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Has Type 2 diabetes on insulin therapy for ≥ 6 months and on their current regimen for ≥3 months prior to study entry.
  2. Their insulin management must be one of the following;

    1. an injection regimen of prandial insulin at least once daily,
    2. or, prandial insulin at least once daily plus basal insulin at least once daily,
    3. or, continuous subcutaneous insulin infusion (CSII) with no plans to change during the study.
  3. HbA1c result ≥7.5% (58 mmol/mol) and ≤12.0% (108 mmol/mol) on entry to the study.
  4. Reports self-testing of blood glucose levels on a regular basis equivalent to a minimum of 10 tests per week, for at least 2 months prior to study entry.
  5. In the investigator's opinion the subject is considered technically capable of using the Abbott Sensor Based Glucose Monitoring System.
  6. In the Investigator's opinion the subject is proactive and therefore willing to modify their diabetes management
  7. Aged 18 years or over.

Exclusion Criteria:

  1. Insulin regimen consists entirely of basal or includes bi-phasic insulin.
  2. Subject is currently prescribed animal insulin.
  3. Subject is currently prescribed steroid therapy or is likely to require steroid therapy for any acute or chronic condition during the study.
  4. Has known allergy to medical grade adhesives.
  5. Currently participating in another device or drug study that could affect glucose measurements or glucose management.
  6. Currently using a Continuous Glucose Monitoring (CGM) device or has used one within the previous 4 months.
  7. Is planning to use a CGM device at any time during the study.
  8. Total daily dose of insulin (TDD) is >1.75iu/kg at entry to the study.
  9. A female subject who is pregnant or planning to become pregnant within the study duration.
  10. Currently receiving dialysis treatment or planning to receive dialysis during the study.
  11. Has experienced an acute myocardial infarction within previous 6 months.
  12. Has a concomitant disease or condition that may compromise patient safety, including unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or any other uncontrolled medical condition.
  13. Has a pacemaker or any other neuro stimulators.
  14. Has experienced any episode of severe hypoglycaemia, requiring third party assistance and/or admission to hospital, in the previous 6 months.
  15. Has experienced any episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS) in the previous 6 months.
  16. In the investigator's opinion, the subject is considered as unsuitable for inclusion in the study for any other reason.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02082184


Locations
France
CHU Haut Lévêque
Bordeaux, France, 33604
Hôpital sainte Marguerite
Marseille, France, 13274
CHU Lapeyronie
Montpellier, France, 34295
CHU. Nancy
Nancy, France
Hopital Guillaume et René Laennec
Nantes, France, 44000
Hospital Lariboisere
Paris, France, 75475
Hôpital Cochin
Paris, France, 75679
Hôpital Rangueil
Toulouse, France, 31059
Germany
Diabetes Zentrum Mergentheim
Bad Mergentheim, Germany, 97980
Praris Dr Karin Schlecht
Eisenach, Germany, 99817
Diabetologische Schwenpunlet Praxis
Hamburg, Germany, 21073
Gemeiusilaftsproxis Fur Junere,
Hamburg, Germany, 22607
Vorstandsmitglied Deutsche Diabetes-Hilfe
Hamburg, Germany
Hohenzollernring
Münster, Germany, 48145
Diabetes Center Quakenbruck
Quakenbrück, Germany, 49610
Diabetes Schwerpunktpraxis Loccum
Rehburg-Loccum, Germany, 31547
An der Pforte
Rosenheim, Germany, 55545
Versdias GmbH
Sulzbach-Rosenberg, Germany
United Kingdom
Ayr Hospital
Ayr, Ayrshire, United Kingdom, KA6 6DX
Diabetes Research, Linda McCartney Centre, Royal Liverpool University Hospital
Liverpool, Cheshire, United Kingdom, L7 8XP
Royal United Hospital
Bath, United Kingdom, BA1 3NG
FRCPath Life and Health Sciences, Aston University
Birmingham, United Kingdom, B4 7ET
University Hospital of North Durham
Durham, United Kingdom, DH1 5TW
The Diabetes Centre, Ipswich Hospital NHS Trust
Ipswich, United Kingdom, IP4 5PD
St. James University Hospital, Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom, LS9 7TF
Rotherham General Hospital
Rotherham, United Kingdom, S60 2UD
Sponsors and Collaborators
Abbott Diabetes Care
Investigators
Principal Investigator: Thomas Haak Research Institute of Diabetes Academy Mergentheim (FIDAM)
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Abbott Diabetes Care
ClinicalTrials.gov Identifier: NCT02082184     History of Changes
Other Study ID Numbers: ADC-CI-APO-12018
First Submitted: March 6, 2014
First Posted: March 10, 2014
Results First Submitted: March 3, 2017
Results First Posted: April 14, 2017
Last Update Posted: May 30, 2017
Last Verified: April 2017

Keywords provided by Abbott Diabetes Care:
Sensing Technology
Type 2 Diabetes,

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases